Parvus Therapeutics
Parvus Therapeutics Inc. is a clinical-stage private biotech developing a proprietary pMHC nanomedicine platform that generates antigen-specific regulatory T cells in vivo to reverse autoimmune disease without broad immunosuppression, for patients across multiple autoimmune indications.
- Company typePrivate
- Founded2009
- HeadquartersSouth San Francisco, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Parvus Therapeutics does
Parvus Therapeutics Inc. is a privately held, clinical-stage biopharmaceutical company headquartered in South San Francisco, California, developing a proprietary class of pMHC (peptide-major histocompatibility complex) nanomedicine drug candidates for the treatment of autoimmune disease. The company's stated scientific foundation derives from the immunology discoveries of founder and Chief Scientific Officer Dr. Pere Santamaria, Professor in the Department of Microbiology & Infectious Diseases and Julia McFarlane Chair in Diabetes Research at the Cumming School of Medicine, University of Calgary, suggesting an academic spin-out origin.
The core technology is a pMHC nanomedicine platform that, unlike conventional autoimmune therapies requiring broad immune suppression, is designed to trigger the in vivo generation of antigen-specific regulatory T cells (Tregs). These Tregs are intended to suppress autoimmune attack on self-tissue while preserving normal immune function, with the platform positioned as applicable to multiple autoimmune indications. The product offering is structured as one platform technology yielding multiple drug candidates (described in the source as 'Navacims'-style pMHC nanomedicines) across the company's pipeline.
Parvus is pre-commercial: the input contains no disclosed revenue, no pricing model, no customers, and no commercial partnerships. The business model is consistent with a clinical-stage biotech — capital is consumed by R&D, with future monetization contingent on either clinical/commercial success of in-house drug candidates or a future licensing/M&A transaction. No parent company, disclosed institutional investors, or partnerships are identified in the source material. Corporate communication is limited to a company website and a LinkedIn page, consistent with a small (11–50 employee) organization focused on development rather than commercial marketing.
Parvus Therapeutics firmographics
Firmographics- Name
- Parvus Therapeutics
- Legal name
- Parvus Therapeutics Inc.
- Website
- https://parvustherapeutics.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Parvus Therapeutics Inc. is a clinical-stage private biotech developing a proprietary pMHC nanomedicine platform that generates antigen-specific regulatory T cells in vivo to reverse autoimmune disease without broad immunosuppression, for patients across multiple autoimmune indications.
- Ownership category
- akta.pro rank
Parvus Therapeutics industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)
- akta.pro secondary industries
- Dendritic Cell & Other APC-based Therapies (HLAAABAF), Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)
Keywords
Where Parvus Therapeutics is headquartered
LocationHeadquarters
- HQ city
- South San Francisco
- HQ country
- United States
- HQ region
- North America
Markets served
Parvus Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Marketing channels1 record
Parvus Therapeutics product offering
Product offeringCore offering
Parvus Therapeutics is a clinical-stage biopharmaceutical company developing proprietary pMHC (peptide-major histocompatibility complex) nanomedicine drug candidates. These candidates trigger in vivo generation of antigen-specific regulatory T cells (Tregs) designed to halt and cure autoimmune disease by restoring organ-specific immune tolerance without compromising normal immune function, in contrast to current treatments that require broad immune system suppression.
Product overview
Parvus Therapeutics is a clinical-stage company developing a proprietary pMHC Nanomedicine Platform that generates novel drug candidates. These pMHC nanomedicine drug candidates trigger in vivo generation of antigen-specific regulatory T cells (Tregs) designed to halt and cure autoimmune disease by restoring organ-specific immune tolerance without compromising normal immune function. The company's pipeline consists of multiple therapeutic candidates developed using this single technology platform.
Differentiator
Problem solved
Functional benefit
Products and services
- pMHC Nanomedicine Platform
Companies that use Parvus Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Parvus Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Parvus Therapeutics partnerships and signals
Strategic signalRecent moves4 records
Expansion highlights3 records
Parvus Therapeutics competitors and assessment
Company assessmentDirect peers
- Sonoma Biotherapeutics: Sonoma Biotherapeutics develops engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, making it a directly comparable peer pursuing Treg-based approaches to restore immune tolerance.
- Abata Therapeutics: Abata Therapeutics is developing engineered Treg cell therapies focused on autoimmune diseases, sharing the Treg-based therapeutic modality and target indication space with Parvus.
- GentiBio: GentiBio is engineering regulatory T cells (Tregs) for autoimmune and inflammatory diseases, directly competing in the Treg therapeutics space with a focus on scalable engineered Treg approaches.
- Selecta Biosciences: Selecta Biosciences (now Cartesian Therapeutics) develops immunomodulatory therapies including tolerance-inducing approaches for autoimmune disease, with overlapping mechanism of antigen-specific immune tolerance.
Emerging players
- Cue Biopharma: Cue Biopharma develops novel T cell engagers and immunomodulators for autoimmune disease and cancer, sharing the immunology platform space though focused on T cell modulators rather than Tregs specifically.
- Cellenkos: Cellenkos is developing regulatory T cell-based therapies for autoimmune and inflammatory diseases, with a parallel focus on Treg therapeutics but using cord blood-derived Tregs.
- Anokion: Anokion develops antigen-specific immune tolerance therapies for autoimmune disease using engineered protein platforms, sharing the antigen-specific tolerance approach to autoimmune indications.
Broad incumbents
- Vir Biotechnology: Vir Biotechnology is a clinical-stage immunology company developing treatments for serious infectious diseases and autoimmune conditions, operating more broadly in immune-mediated disease therapeutics with greater resources.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
Parvus Therapeutics social profiles
Digital presenceParvus Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Parvus Therapeutics leadership team
Management profileNumber of profiles
Profiles2 records
Parvus Therapeutics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Parvus Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Parvus Therapeutics
What does Parvus Therapeutics do?
Parvus Therapeutics is a clinical-stage biopharmaceutical company developing proprietary pMHC (peptide-major histocompatibility complex) nanomedicine drug candidates. These candidates trigger in vivo generation of antigen-specific regulatory T cells (Tregs) designed to halt and cure autoimmune disease by restoring organ-specific immune tolerance without compromising normal immune function, in contrast to current treatments that require broad immune system suppression.
Is Parvus Therapeutics a public or private company?
Parvus Therapeutics is a private company. It is classified as unknown and is currently operating.
When was Parvus Therapeutics founded?
Parvus Therapeutics was founded in 2009. It employs 11 to 50 people.
Where is Parvus Therapeutics based?
Parvus Therapeutics is headquartered in South San Francisco, United States, in the North America region.
Who are Parvus Therapeutics's main competitors?
Direct peers on record are Sonoma Biotherapeutics, Abata Therapeutics, GentiBio and Selecta Biosciences. Emerging players are Cue Biopharma, Cellenkos and Anokion. Vir Biotechnology is listed as a broad incumbent.
Does Parvus Therapeutics have an API?
No public API is recorded for Parvus Therapeutics.
What industry is Parvus Therapeutics in?
Parvus Therapeutics's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAANAK, Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies), with a secondary code of HLAAABAF, Dendritic Cell & Other APC-based Therapies. Its NAICS code is 325414 and its SIC code is 2836.